Unnamed: 0,title,date,stock,sentiment
1071572.0,RedHill Biopharma Submits COVID-19 Coronavirus Clinical Trial Application For Phase 2/3 Study With Opaganib,2020-06-10 07:01:00-04:00,RDHL,neutral
1071573.0,RedHill Biopharma To Present Development Program With Opaganib For COVID-19 Coronavirus And Phase 3 Program For RHB-204 On Mon. June 15.,2020-06-08 07:09:00-04:00,RDHL,neutral
1071574.0,RedHill Biopharma shares are trading lower after the company reported worse-than-expected Q1 sales results.,2020-05-27 10:22:00-04:00,RDHL,neutral
1071575.0,Redhill Biopharma shares are trading higher after the company reported better-than-expected Q1 EPS results. The stock has reversed and is now trading lower.,2020-05-27 08:22:00-04:00,RDHL,neutral
1071576.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,RDHL,positive
1071577.0,Recap: Redhill Biopharma Q1 Earnings,2020-05-27 07:23:00-04:00,RDHL,neutral
1071578.0,"Redhill Biopharma Q1 EPS $(0.05) Beats $(0.24) Estimate, Sales $1.06M Miss $4.38M Estimate",2020-05-27 07:04:00-04:00,RDHL,negative
1071579.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2020-05-24 14:40:00-04:00,RDHL,neutral
1071580.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-05-12 07:33:00-04:00,RDHL,neutral
1071581.0,Why Redhill Biopharma's Stock Is Trading Higher Today,2020-05-08 11:26:00-04:00,RDHL,neutral
1071582.0,Redhill Biopharma shares are trading higher after the company received FDA approval for its coronavirus clinical study with Opaganib in the US.,2020-05-08 09:05:00-04:00,RDHL,positive
1071583.0,17 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-08 07:50:00-04:00,RDHL,neutral
1071584.0,RedHill Biopharma Reports FDA Approval Of Coronavirus Study With Opaganib In US,2020-05-08 07:01:00-04:00,RDHL,positive
1071585.0,Redhill Biopharma shares are trading higher after the company highlighted the publication of Talicia pivotal Phase 3 Study results in Annals of Internal Medicine.,2020-05-05 08:50:00-04:00,RDHL,positive
1071586.0,RedHill Biopharma Highlights Publication Of Talicia Pivotal Phase 3 Study Results In Annals Of Internal Medicine,2020-05-05 07:23:00-04:00,RDHL,neutral
1071587.0,RedHill's CEO On Biopharma's 'Two Shots On Goal' For Coronavirus Drug,2020-05-01 11:39:00-04:00,RDHL,neutral
1071588.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,RDHL,positive
1071589.0,82 Biggest Movers From Yesterday,2020-04-29 04:30:00-04:00,RDHL,neutral
1071590.0,56 Stocks Moving In Tuesday's Mid-Day Session,2020-04-28 12:27:00-04:00,RDHL,neutral
1071591.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-28 10:18:00-04:00,RDHL,neutral
1071592.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,RDHL,neutral
1071593.0,"RedHill Biopharma Reports Prime Therapeutics Added Talicia To Netresults A-Series National Formulary as Unrestricted, Preferred Brand For H. Pylori Treatment, Effective Jul. 1, 2020",2020-04-28 07:13:00-04:00,RDHL,positive
1071594.0,96 Biggest Movers From Yesterday,2020-04-28 04:22:00-04:00,RDHL,neutral
1071595.0,72 Stocks Moving In Monday's Mid-Day Session,2020-04-27 12:34:00-04:00,RDHL,neutral
1071596.0,Redhill Biopharma shares are trading higher after the company says six coronavirus patients were treated with the company's Opaganib under compassionate use which showed objective clinical improvement.,2020-04-27 09:08:00-04:00,RDHL,positive
1071597.0,"UPDATE: RedHill Says 'Five of the six patients analyzed were weaned from oxygen, and three were discharged from the hospital within days of treatment initiation'",2020-04-27 07:03:00-04:00,RDHL,neutral
1071598.0,RedHill Biopharma Says Six Coronavirus Patients Treated With Co.'s Opaganib Under Compassionate Use Show 'Objective Clinical Improvement',2020-04-27 07:03:00-04:00,RDHL,positive
1071599.0,"RedHill Biopharma Reports Deal With National Institute Of Allergy, Infectious Diseases To Provide RHB-107 For Testing In Non-Clinical Studies For Activity Against Coronavirus Infection",2020-04-20 09:16:00-04:00,RDHL,neutral
1071600.0,95 Biggest Movers From Friday,2020-04-20 05:00:00-04:00,RDHL,neutral
1071601.0,IND For Coronavirus COVID-19 With Opaganib Submitted To FDA By RedHill Biopharma,2020-04-17 13:29:00-04:00,RDHL,neutral
1071602.0,58 Stocks Moving In Friday's Mid-Day Session,2020-04-17 12:31:00-04:00,RDHL,neutral
1071603.0,"RedHill Bipharma Offers Added Update On Coronavrius Compassionate Use With Opaganib In Israel: All 5 Patients Shown Improve C-Reactive Protein, 4 Patients Showing Measurable Clinical Improvement",2020-04-17 09:54:00-04:00,RDHL,positive
1071604.0,78 Biggest Movers From Yesterday,2020-04-15 04:45:00-04:00,RDHL,neutral
1071605.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-04-14 12:52:00-04:00,RDHL,neutral
1071606.0,17 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-04-14 07:57:00-04:00,RDHL,neutral
1071607.0,31 Stocks Moving in Tuesday's Pre-Market Session,2020-04-14 07:10:00-04:00,RDHL,neutral
1071608.0,86 Biggest Movers From Yesterday,2020-04-14 05:19:00-04:00,RDHL,negative
1071609.0,63 Stocks Moving In Monday's Mid-Day Session,2020-04-13 12:35:00-04:00,RDHL,neutral
1071610.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-04-13 07:39:00-04:00,RDHL,neutral
1071611.0,Redhill Biopharma shares are trading higher after the company announced both of its coronavirus patients treated with its Opaganib treatment showed improvement.,2020-04-13 07:36:00-04:00,RDHL,positive
1071612.0,RedHill Biopharma Says Both Coronavirus Patients Treated With its Opaganib Showed Improvement,2020-04-13 07:04:00-04:00,RDHL,positive
1071613.0,84 Biggest Movers From Yesterday,2020-04-07 05:47:00-04:00,RDHL,neutral
1071614.0,66 Stocks Moving In Monday's Mid-Day Session,2020-04-06 12:32:00-04:00,RDHL,neutral
1071615.0,RedHill Biopharma Announces Approval Of Compassionate Use Of Opaganib For Coronavirus In Italy,2020-04-06 08:24:00-04:00,RDHL,positive
1071616.0,16 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-04-06 07:46:00-04:00,RDHL,neutral
1071617.0,26 Stocks Moving in Monday's Pre-Market Session,2020-04-06 07:12:00-04:00,RDHL,neutral
1071618.0,"With The World In The Midst Of A Pandemic, Attention Turns To Life Sciences",2020-03-25 16:56:00-04:00,RDHL,neutral
1071619.0,"RedHill Biopharma Shares Spike Following Mention Of Malaria Treatment Hydroxychloroquine During White House Coronavirus Task Force Presser; BZ NOTE: Co. Is Pursuing Exploratory Program Of Opaganib, RHB-107 In Combo With Hydroxychloroquine",2020-03-19 12:00:00-04:00,RDHL,positive
1071620.0,RedHill Biopharma Shares Halted On Circuit Breaker,2020-03-19 11:54:00-04:00,RDHL,positive
1071621.0,40 Stocks Moving in Thursday's Pre-Market Session,2020-03-19 07:37:00-04:00,RDHL,neutral
1071622.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,RDHL,neutral
1071623.0,95 Stocks Moving In Monday's Mid-Day Session,2020-03-16 12:00:00-04:00,RDHL,neutral
1071624.0,144 Biggest Movers From Friday,2020-03-16 05:03:00-04:00,RDHL,neutral
1071625.0,88 Stocks Moving In Friday's Mid-Day Session,2020-03-13 12:38:00-04:00,RDHL,neutral
1071626.0,"RedHill Biopharma Reports Preferred Position For Talicia On Express Scripts' National Preferred Formulary, Effective Mar. 13 2020",2020-03-13 07:10:00-04:00,RDHL,positive
1071627.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,RDHL,negative
1071628.0,"H.C. Wainwright Reiterates Buy on Redhill Biopharma, Lowers Price Target to $14",2020-03-05 07:50:00-05:00,RDHL,negative
1071629.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,RDHL,negative
1071630.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,RDHL,neutral
1071631.0,140 Biggest Movers From Yesterday,2020-02-28 05:00:00-05:00,RDHL,neutral
1071632.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,RDHL,negative
1071633.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,RDHL,positive
1071634.0,Stocks That Hit 52-Week Lows On Wednesday,2020-02-26 11:14:00-05:00,RDHL,negative
1071635.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,RDHL,negative
1071636.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,RDHL,negative
1071637.0,RedHill Biopharma Enters $115M Non-Dilutive Financing Agreement with HealthCare Royalty Partners,2020-02-25 05:17:00-05:00,RDHL,positive
1071638.0,RedHill Biopharma Acquires Rights to Movantik from AstraZeneca for $52.5M Upfront Plus $15M 18 Months after Closing,2020-02-25 05:16:00-05:00,RDHL,neutral
1071639.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,RDHL,negative
1071640.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,RDHL,negative
1071641.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,RDHL,negative
1071642.0,Stocks That Hit 52-Week Lows On Monday,2020-02-03 11:53:00-05:00,RDHL,negative
1071643.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,RDHL,negative
1071644.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,RDHL,neutral
1071645.0,RedHill Biopharma To Focus Commercial Efforts On Talicia And Aemcolo; Co. Discontinuing Promotion Of Legacy Products,2020-01-21 07:16:00-05:00,RDHL,neutral
1071646.0,RedHill Biopharma Regains Rights To Its Proprietary Bowel Preparation RHB-106,2020-01-02 09:01:00-05:00,RDHL,neutral
1071647.0,20 Stocks Moving In Monday's Pre-Market Session,2019-12-09 07:49:00-05:00,RDHL,neutral
1071648.0,"Redhill Biopharma Q3 EPS $(0.03) Beats $(0.38) Estimate, Sales $1.4M Miss $1.77M Estimate",2019-11-19 07:03:00-05:00,RDHL,negative
1071649.0,"Earnings Scheduled For November 19, 2019",2019-11-19 04:01:00-05:00,RDHL,neutral
1071650.0,"The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict",2019-11-10 16:08:00-05:00,RDHL,positive
1071651.0,46 Biggest Movers From Yesterday,2019-11-05 04:45:00-05:00,RDHL,neutral
1071652.0,35 Stocks Moving In Monday's Mid-Day Session,2019-11-04 13:37:00-05:00,RDHL,neutral
1071653.0,24 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-04 08:13:00-05:00,RDHL,neutral
1071654.0,21 Stocks Moving In Monday's Pre-Market Session,2019-11-04 07:56:00-05:00,RDHL,neutral
1071655.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2019-11-04 07:29:00-05:00,RDHL,neutral
1071656.0,Redhill Biopharma shares are trading higher after the company announced FDA approval of its Talicia for treatment of H Pylori in adults.,2019-11-04 06:51:00-05:00,RDHL,positive
1071657.0,Redhill Biopharma Announces FDA  Approval of Talicia for Treatment of H. Pylori in Adults,2019-11-04 06:06:00-05:00,RDHL,positive
1071658.0,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,2019-11-01 08:05:00-04:00,RDHL,neutral
1071659.0,RedHill Biopharma To Present New Phase 3 Data On RHB-105 And RHB-104 At The American College Of Gastroenterology 2019 Annual Meeting Oct. 25-30,2019-10-28 09:09:00-04:00,RDHL,neutral
1071660.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,RDHL,neutral
1071661.0,38 Stocks Moving In Friday's Mid-Day Session,2019-10-18 12:30:00-04:00,RDHL,neutral
1071662.0,32 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-18 08:34:00-04:00,RDHL,neutral
1071663.0,27 Stocks Moving in Friday's Pre-Market Session,2019-10-18 08:29:00-04:00,RDHL,neutral
1071664.0,Redhill Biopharma Announces $36M Strategic Investment by Cosmo Pharmaceuticals and U.s. Rights to Approved Travelers' Diarrhea Drug Aemcolo,2019-10-18 06:03:00-04:00,RDHL,positive
1071665.0,64 Biggest Movers From Yesterday,2019-10-15 05:07:00-04:00,RDHL,neutral
1071666.0,58 Biggest Movers From Friday,2019-10-14 03:51:00-04:00,RDHL,neutral
1071667.0,"RedHill Biopharma Offers Full Results From MAP US Phase 3 Study, Supportive Top-Line Results From MAP US2 Open-Label Extension Study With RHB-104 In Crohn's Disease",2019-10-11 09:01:00-04:00,RDHL,positive
1071668.0,RedHill Biopharma Offers R&D Update For H2'2019,2019-09-26 08:04:00-04:00,RDHL,neutral
1071669.0,66 Biggest Movers From Yesterday,2019-09-04 05:07:00-04:00,RDHL,neutral
1071670.0,60 Biggest Movers From Yesterday,2019-07-24 04:57:00-04:00,RDHL,neutral
1071671.0,"Redhill Biopharma Q2 EPS $(0.04) Beats $(0.35) Estimate, Sales $1.563M Miss $2.16M Estimate",2019-07-23 07:17:00-04:00,RDHL,negative
1071672.0,40 Biggest Movers From Friday,2019-07-15 05:47:00-04:00,RDHL,neutral
1071673.0,36 Stocks Moving In Friday's Mid-Day Session,2019-07-12 12:38:00-04:00,RDHL,neutral
1071674.0,"Benzinga's Top Upgrades, Downgrades For July 12, 2019",2019-07-12 08:55:00-04:00,RDHL,positive
1071675.0,"WBB Securities Upgrades Redhill Biopharma to Strong Buy, Announces $17 Price Target",2019-07-12 07:15:00-04:00,RDHL,positive
1071676.0,RedHill Biopharma Reports FDA Accepted New Drug Application For Talicia,2019-07-03 07:15:00-04:00,RDHL,positive
1071677.0,RedHill Biopharma Receives Allowance For New US Patent Covering RHB-104 For Crohn's Disease And RHB-204 For NTM Infections,2019-06-10 08:01:00-04:00,RDHL,neutral
1071678.0,"Redhill Biopharma Q1 EPS $(0.03) Beats $(0.35) Estimate, Sales $1.737M Miss $2.76M Estimate",2019-05-07 07:26:00-04:00,RDHL,negative
1071679.0,RedHill Biopharma Submits NDA for Talicia for H. pylori Infection,2019-05-07 06:11:00-04:00,RDHL,neutral
1071680.0,"Benzinga's Top Upgrades, Downgrades For March 12, 2019",2019-03-12 09:29:00-04:00,RDHL,positive
1071681.0,"WBB Securities Upgrades Redhill Biopharma to Buy, Announces $17 Price Target",2019-03-12 07:41:00-04:00,RDHL,positive
1071682.0,RedHill Biopharma Granted Patents for Talicia in Japan and Europe,2019-03-04 08:08:00-05:00,RDHL,positive
1071683.0,"RedHill Biopharma FY18 EPS $(0.17) vs $(0.26) In FY17, Sales $8.36M vs $4.007M In FY17",2019-02-26 07:18:00-05:00,RDHL,neutral
1071684.0,RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA For H. Pylori Infection,2019-01-17 08:02:00-05:00,RDHL,neutral
1071685.0,"Benzinga's Top Upgrades, Downgrades For December 31, 2018",2018-12-31 09:18:00-05:00,RDHL,positive
1071686.0,RedHill Biopharma Shares To Resume Trade At 9:50 a.m. EST,2018-12-06 08:59:00-05:00,RDHL,positive
1071687.0,RedHill Biopharma Prices ~2.86M Share Offering At $7.ADS For Proceeds Of 20M,2018-12-06 08:45:00-05:00,RDHL,positive
1071688.0,"RedHill Biopharma Reports Offering Of ADSs, No Terms Disclosed",2018-12-04 16:03:00-05:00,RDHL,negative
1071689.0,Redhill Biopharma Shares Halted News Pending,2018-12-04 16:00:00-05:00,RDHL,positive
1071690.0,"Redhill Biopharma Shares Resume Trade, Up 7%",2018-12-03 09:50:00-05:00,RDHL,positive
1071691.0,"Redhill Biopharma Halted, News Pending",2018-12-03 06:56:00-05:00,RDHL,neutral
1071692.0,"The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal",2018-11-16 08:08:00-05:00,RDHL,positive
1071693.0,"Redhill Biopharma Ltd. Q3 EPS $(0.04) Up From $(0.09) YoY, Sales $2.21M Miss $2.69M Estimate",2018-11-13 07:01:00-05:00,RDHL,negative
1071694.0,Redhill Biopharma Holding Analyst/Investor Webcast On TALICIA Today at 8:30am ET,2018-10-30 07:04:00-04:00,RDHL,neutral
1071695.0,"Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?",2018-10-29 13:10:00-04:00,RDHL,positive
1071696.0,Redhill Biopharma Says Final Patient Assessed in Phase III Confirmatory Study Of TALICIA,2018-10-24 08:37:00-04:00,RDHL,neutral
1071697.0,RedHill Biopharma To Present Previously Disclosed Data From Phase III Study Of RHB-104 In Crohn's Disease At United European Gastroenterology (UEG) Week 2018,2018-10-22 09:28:00-04:00,RDHL,positive
1071698.0,"RedHill Biopharma Announces Conclusion Of End-of-Phase II Meeting With FDA On BEKINDA; Co. Plans To Finalize Design Of Two Phase 3 Studies To Accelerate Partnership Discussions, Including US Co-Promotion Opportunities",2018-09-12 07:12:00-04:00,RDHL,positive
1071699.0,RedHill Biopharma Reports Study Of YELIVA For Cholangiocarcinoma Advanced To Second Stage Of Phase IIa Trial,2018-09-06 08:16:00-04:00,RDHL,positive
1071700.0,RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection,2018-09-04 07:02:00-04:00,RDHL,neutral
1071701.0,"Redhill Biopharma Ltd. - American Depositary Shares Q2 EPS $(0.05) Beats $(0.45) Estimate, Sales $2.35M Miss $2.77M Estimate",2018-08-30 07:07:00-04:00,RDHL,positive
1071702.0,"Earnings Scheduled For August 30, 2018",2018-08-30 05:19:00-04:00,RDHL,neutral
1071703.0,"RedHill Biopharma Receives Allowance for New US Patent Covering RHB-106, an Encapsulated Bowel Preparation",2018-08-20 07:02:00-04:00,RDHL,neutral
1071704.0,Redhill Biopharma Receives a US Patent Covering RHB-104 for Crohn's Disease and RHB-204 for NTM Infections,2018-08-13 07:05:00-04:00,RDHL,neutral
1071705.0,"RedHill Biopharma Announces Pricing of A 4,166,667 Share ADS Offering at $6/ADS Or $25M Total",2018-08-09 09:10:00-04:00,RDHL,positive
1071706.0,26 Stocks Moving In Monday's Pre-Market Session,2018-08-06 08:04:00-04:00,RDHL,neutral
1071707.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-08-02 08:05:00-04:00,RDHL,neutral
1071708.0,30 Stocks Moving In Wednesday's Pre-Market Session,2018-08-01 08:27:00-04:00,RDHL,neutral
1071709.0,RedHill Biopharma Adds Clarification on a Secondary Endpoint Following a Monday Press Release,2018-08-01 08:20:00-04:00,RDHL,neutral
1071710.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2018-08-01 07:38:00-04:00,RDHL,neutral
1071711.0,65 Biggest Movers From Yesterday,2018-08-01 04:36:00-04:00,RDHL,neutral
1071712.0,52 Stocks Moving In Tuesday's Mid-Day Session,2018-07-31 12:38:00-04:00,RDHL,neutral
1071713.0,Redhill Biopharma Shares Down 13.5% For The Session After Spiking Over 26% On Monday Following Phase III Crohn's Disease Study Results,2018-07-31 10:59:00-04:00,RDHL,positive
1071714.0,30 Stocks Moving In Tuesday's Pre-Market Session,2018-07-31 08:00:00-04:00,RDHL,neutral
1071715.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Mon., Jul. 30, 2018",2018-07-30 10:44:00-04:00,RDHL,positive
1071716.0,RedHill Earns Long-Awaited Boost On Positive Crohn's Data,2018-07-30 10:15:00-04:00,RDHL,positive
1071717.0,"Redhill Biopharma Shares Up 26% After Co. Announces Positive Top-Line Results From Phase III Study Of RHB-104 For Crohn's Disease, Meeting Primary And Key Secondary Endpoints And Demonstrating Statistically Significant Benefit Over Placebo",2018-07-30 08:47:00-04:00,RDHL,positive
1071718.0,28 Stocks Moving In Monday's Pre-Market Session,2018-07-30 08:30:00-04:00,RDHL,neutral
1071719.0,RedHill Biopharma's Phase III Study of RHB-104 in Crohn's Disease Met Primary and 'Key' Secondary Endpoints,2018-07-30 07:01:00-04:00,RDHL,neutral
1071720.0,Redhill Biopharma Halted; Pending News,2018-07-30 04:02:00-04:00,RDHL,neutral
1071721.0,RedHill Biopharma Starts Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi,2018-07-25 08:02:00-04:00,RDHL,neutral
1071722.0,"RedHill Sees Completion Of Enrollment In Phase III ERADICATE Hp2 Study In Coming Weeks, Will Report Top-Line Results In Q4'18",2018-07-24 08:24:00-04:00,RDHL,neutral
1071723.0,RedHill Biopharma Reports Enrollment Of 400th Patient In Confirmatory Phase III Study With TALICIA For H. Pylori Infection,2018-07-24 08:23:00-04:00,RDHL,neutral
1071724.0,Redhill Biopharma Shares Down 6% Premarket After Co. Filed For Potential $175M Mixed Offering,2018-07-23 09:00:00-04:00,RDHL,positive
1071725.0,RedHill Biopharma Files for Potential $175M Mixed Offering,2018-07-23 08:09:00-04:00,RDHL,neutral
1071726.0,"Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4",2018-07-17 08:37:00-04:00,RDHL,neutral
1071727.0,RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn's Disease,2018-07-02 07:00:00-04:00,RDHL,neutral
1071728.0,RedHill BioPharma Patiently Awaits Market Recognition As It Achieves Consistent Trial Success,2018-06-29 11:49:00-04:00,RDHL,positive
1071729.0,"RedHill Biopharma Shares Up 9.8%; Yesterday Co. Announced Co-Promotion Agreement With Jaguar Health's Napo Pharm, Giving RedHill The Right To Co-Promote Mytesi In The U.S.; RedHill Expects  To Initiate Its Promotion 'In the coming weeks'",2018-06-29 11:48:00-04:00,RDHL,positive
1071730.0,"RedHill Biopharma's Goldberg, In Benzinga Interview, Says Strategic Goal Of Commercial Infrastructure Is Paving The Way To Launch Talicia (Prospective H. pylori Treatment With Data Due Q4 This Year), 'That's really the home run.'",2018-06-29 11:28:00-04:00,RDHL,neutral
1071731.0,"RedHill Biopharma Chief Business Officer Guy Goldberg, In Benzinga Interview, Says Co. Has No Set Financing Plan But Isn't 'Desperate For Cash,' Could Look At Offerings/Licensing Ex-U.S. Rights For Products Depending On Outcome Of Near Term Data Releases",2018-06-29 11:28:00-04:00,RDHL,positive
1071732.0,"Benzinga's Top Upgrades, Downgrades For June 25, 2018",2018-06-25 09:18:00-04:00,RDHL,positive
1071733.0,"Ladenburg Thalmann Initiates Coverage On Redhill Biopharma with Buy Rating, Announces $20 Price Target",2018-06-25 08:26:00-04:00,RDHL,neutral
1071734.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-05-29 08:13:00-04:00,RDHL,neutral
1071735.0,RedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy,2018-05-29 08:04:00-04:00,RDHL,neutral
1071736.0,"Redhill Biopharma Ltd. - American Depositary Shares Q1 EPS $(0.05) Beats $(0.46) Estimate, Sales $2.445M Beat $2.32M Estimate",2018-05-08 07:13:00-04:00,RDHL,positive
1071737.0,RedHill Biopharma Reports Enrollment Of 300th Patient In Confirmatory Phase III Study Of TALICIA For H. pylori Infection,2018-05-04 07:08:00-04:00,RDHL,neutral
1071738.0,Redhill Biopharma Says Plans To Meet With FDA in Q2 2018 to Discuss Design for One or Two Pivotal Phase III Studies With Bekinda 12 Mg for IBS-D,2018-04-09 07:08:00-04:00,RDHL,neutral
1071739.0,CORRECTION: RedHill News From Tues. Was 2 Abstracts Related To Phase III GUARD Study Of BEKINDA 24 mg Accepted For Oral Presentations At SAEM '18 Meeting; The initial headline suggested the trial met primary endpoint; this was reported in Jun. '17,2018-03-27 09:31:00-04:00,RDHL,positive
1071740.0,RedHill Biopharma Shares Up 1.3%; In Earlier 6-K Co. Mentioned Plans To Meet With FDA In Q2 2018 To Discuss Phase III Studies of BEKINDA in IBS-D,2018-03-26 11:27:00-04:00,RDHL,positive
1071741.0,"RedHill Biopharma Reports Q4 Operating Loss $14.4M vs $9M In Same Qtr. Last Year, Sales $2M vs $1.9M Est.",2018-02-22 07:19:00-05:00,RDHL,negative
1071742.0,45 Biggest Movers From Friday,2018-01-29 04:17:00-05:00,RDHL,neutral
1071743.0,41 Stocks Moving In Friday's Mid-Day Session,2018-01-26 13:04:00-05:00,RDHL,neutral
1071744.0,"Benzinga's Top Upgrades, Downgrades For January 26, 2018",2018-01-26 09:14:00-05:00,RDHL,positive
1071745.0,21 Stocks Moving In Friday's Pre-Market Session,2018-01-26 08:28:00-05:00,RDHL,neutral
1071746.0,"Nomura Initiates Coverage On Redhill Biopharma with Buy Rating, Announces $18.00 Price Target",2018-01-26 07:40:00-05:00,RDHL,neutral
1071747.0,"RedHill Biopharma, Express Scripts' Inside Rx Report Addition Of EnteraGram To Savings Program For Uninsured, Underinsured Patients",2018-01-17 07:12:00-05:00,RDHL,neutral
1071748.0,13G Filing Shows Capital Management Taking 6.6% Stake In RedHill Biopharma,2018-01-16 16:10:00-05:00,RDHL,neutral
1071749.0,RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 for Cholangiocarcinoma at Mayo Clinic and MD Anderson,2017-12-22 07:01:00-05:00,RDHL,neutral
1071750.0,"RedHill Biopharma Reports Q3 EPS $(0.09) vs $(0.63) Est., Sales $1.523M vs $1.14M Est.",2017-11-13 07:37:00-05:00,RDHL,neutral
1071751.0,RedHill Biopharma Reports Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease,2017-11-09 07:18:00-05:00,RDHL,neutral
1071752.0,57 Biggest Movers From Yesterday,2017-11-09 05:16:00-05:00,RDHL,neutral
1071753.0,Mid-Afternoon Market Update: Container Store Climbs Following Strong Q2 Results; LendingClub Shares Plunge,2017-11-08 14:32:00-05:00,RDHL,positive
1071754.0,46 Stocks Moving In Wednesday's Mid-Day Session,2017-11-08 12:31:00-05:00,RDHL,neutral
1071755.0,Mid-Day Market Update: CECO Environmental Drops After Q3 Results; Forterra Shares Surge,2017-11-08 12:01:00-05:00,RDHL,positive
1071756.0,Mid-Morning Market Update: Markets Open Lower; Humana Earnings Top Expectations,2017-11-08 10:03:00-05:00,RDHL,negative
1071757.0,RedHill Biopharma Prices 4.091M ADS Offering At $5.50 Per ADS,2017-11-08 09:16:00-05:00,RDHL,neutral
1071758.0,32 Stocks Moving In Wednesday's Pre-Market Session,2017-11-08 08:08:00-05:00,RDHL,neutral
1071759.0,"RedHill Biopharma Reports Offering Of ADSs, No Amount Disclosed",2017-11-07 16:09:00-05:00,RDHL,negative
1071760.0,"RedHill Biopharma, IntelGenx Report Submission Of NDA For RIZAPORT For Migraines",2017-11-01 07:15:00-04:00,RDHL,neutral
1071761.0,IntelGenx and RedHill Biopharma Resubmit RIZAPORT New Drug Application to the FDA,2017-11-01 07:14:00-04:00,RDHL,neutral
1071762.0,RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104,2017-10-23 07:00:00-04:00,RDHL,neutral
1071763.0,35 Biggest Movers From Friday,2017-10-23 06:07:00-04:00,RDHL,neutral
1071764.0,32 Stocks Moving In Friday's Mid-Day Session,2017-10-20 12:27:00-04:00,RDHL,neutral
1071765.0,25 Stocks Moving In Friday's Pre-Market Session,2017-10-20 08:03:00-04:00,RDHL,neutral
1071766.0,RedHill Biopharma Reports Received FDA Orphan Drug Designation For MESUPRON For Pancreatic Cancer,2017-10-20 07:03:00-04:00,RDHL,negative
1071767.0,"RedHill Biopharma Shares Indicated Up 1.6% Premarket; Co. Issues Release Highlighting Poster Presentation At AACR-NCI-EORTC Conference, But No New Data Was Included In Release",2017-10-19 08:57:00-04:00,RDHL,negative
1071768.0,"Seaport Global Initiates Coverage On Redhill Biopharma Ltd. - American Depositary Shares with Buy Rating, Announces $19.00 Price Target",2017-10-06 09:55:00-04:00,RDHL,positive
1071769.0,"Benzinga's Top Upgrades, Downgrades For October 6, 2017",2017-10-06 09:24:00-04:00,RDHL,positive
1071770.0,Mid-Afternoon Market Update: Tile Shop Drops On Weak Sales Forecast; Endocyte Shares Spike Higher,2017-10-03 14:36:00-04:00,RDHL,negative
1071771.0,15 Biggest Mid-Day Losers For Tuesday,2017-10-03 12:34:00-04:00,RDHL,negative
1071772.0,Mid-Day Market Update: Dow Rises 70 Points; RedHill Biopharma Shares Slide,2017-10-03 12:00:00-04:00,RDHL,positive
1071773.0,Mid-Morning Market Update: Markets Open Higher; Paychex Profit Beats Estimates,2017-10-03 10:39:00-04:00,RDHL,positive
1071774.0,RedHill Biopharma Shares To Resume Trade At 7:30 a.m. EDT,2017-10-03 07:07:00-04:00,RDHL,positive
1071775.0,UPDATE: RedHill Is Designing A Confirmatory Phase III Study To Support NDA For BEKINDA,2017-10-03 07:02:00-04:00,RDHL,positive
1071776.0,"UPDATE: RedHill Planning To Pursue Phase III Studies With BEKINDA, Intends To Meet With FDA By Early 2018 To Discuss Path Forward",2017-10-03 07:01:00-04:00,RDHL,neutral
1071777.0,RedHill Biopharma Offers Top-Line Results From Phase II Study Of BEKINDA In Patients With IBS-D: Primary Endpoint Met,2017-10-03 07:01:00-04:00,RDHL,neutral
1071778.0,RedHill Biopharma Shares Halted News Pending,2017-10-03 06:58:00-04:00,RDHL,positive
1071779.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-02 08:11:00-04:00,RDHL,neutral
1071780.0,UPDATE: RedHill Sees ~$14M In Cost Savings,2017-10-02 07:09:00-04:00,RDHL,neutral
1071781.0,UPDATE: RedHill Says Has Curtailed 'target sample size in the ongoing first Phase III study with RHB-104 for Crohn's disease from 410 to ~325 subjects',2017-10-02 07:08:00-04:00,RDHL,neutral
1071782.0,"RedHill Biopharma Reports Acceleration Of RHB-104 Phase III Study In Crohn's Disease, Top-Line Results Expected Mid-'18",2017-10-02 07:08:00-04:00,RDHL,neutral
1071783.0,18 Biggest Mid-Day Gainers For Thursday,2017-09-28 12:14:00-04:00,RDHL,neutral
1071784.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-09-28 08:35:00-04:00,RDHL,neutral
1071785.0,Redhill Biopharma Shares Up 2.05% Premarket; Co. Earlier Announced Notice Of Allowance For U.S. Patent Covering YELIVA and MESUPRON In Combination With An Antibiotic,2017-09-18 08:57:00-04:00,RDHL,positive
1071786.0,RedHill Biopharma Announces Data and Safety Monitoring Board Recommendation to Continue Phase III RHB-104 Study,2017-07-31 08:12:00-04:00,RDHL,positive
1071787.0,"RedHill Biopharma Q2 EPS $0.06 vs $(0.58) Est., Sales $483K vs $220K Est., May Not Compare",2017-07-25 07:03:00-04:00,RDHL,neutral
1071788.0,Redhill Biopharma Expects to Share Top Line Results in September,2017-07-17 08:05:00-04:00,RDHL,positive
1071789.0,"RedHill Biopharma Reports Last Patient Visit in BEKINDA Phase II Study for IBS-D, Top-Line Results Expected Sept. 2017",2017-07-17 08:02:00-04:00,RDHL,neutral
1071790.0,UPDATE: RedHill Says 300 Patients Of Planned 410 Total Patients Enrolled In Ongoing Phase 3 MAP US Study,2017-07-12 08:03:00-04:00,RDHL,neutral
1071791.0,UPDATE: RedHill Biopharma Says DSMB Recommendation Planned To Be Announced By Early Aug. 2017,2017-07-12 08:03:00-04:00,RDHL,neutral
1071792.0,UPDATE: RedHill Biopharma Says DSMB Meeting Of RHB-104 Phase 3 Study For Crohn's Planned To Be Held In Late Jul. 2017,2017-07-12 08:02:00-04:00,RDHL,neutral
1071793.0,"RedHill Biopharma Offers Expected Timeline For DSMB Meeting, Offers Update On Enrollment In RHB-104 Phase 3 Study For Crohn's",2017-07-12 08:01:00-04:00,RDHL,neutral
1071794.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-06-15 08:04:00-04:00,RDHL,neutral
1071795.0,RedHill Biopharma Reports Confirmatory Phase III Study Started with RHB-105 (TALICIA) for H. pylori Infection,2017-06-15 08:02:00-04:00,RDHL,neutral
1071796.0,RedHill Biopharma Higher Off Positive Phase III Results For BEKINDA,2017-06-14 10:09:00-04:00,RDHL,positive
1071797.0,"RedHill Biopharma Reports Results From Phase III Trial With BEKINDA For Acute Gastroenteritis: Met Primary Endpoint, Was Shown To Be Effective, Safe, Well Tolerated",2017-06-14 08:02:00-04:00,RDHL,positive
1071798.0,RedHill Biopharma Press Release Confirms Co. Has Initiated U.S. Commercial Activities For Donnatal and EnteraGam,2017-06-13 08:52:00-04:00,RDHL,neutral
1071799.0,Concordia International Reports RedHill Biopharma Has Started Promoting Donnatal in the U.S.,2017-06-13 08:04:00-04:00,RDHL,positive
1071800.0,The Market In 5 Minutes,2017-06-06 09:00:00-04:00,RDHL,neutral
1071801.0,Exclusive: RedHill Biopharma CEO Talks Steering His Company Through A Year Heavy With Potential Catalysts,2017-06-05 15:54:00-04:00,RDHL,positive
1071802.0,"RedHill Biopharma CEO Confirms To Benzinga That It Will Launch 2 Products, Donnatal And EnteraGam, This Month",2017-06-05 15:51:00-04:00,RDHL,neutral
1071803.0,"UPDATE: RedHill Biopharma CEO Tells Benzinga FDA Has Told Co. Strong Enough Results In Its BEKINDA Phase 3 Trial Will Warrant NDA Application Without Further Study, Says FDA Hasn't Communicated Exact Significance That Must Be Met",2017-06-05 15:51:00-04:00,RDHL,positive
1071804.0,"RedHill Biopharma CEO In Interview With Benzinga Says Co. Can't Launch BEKINDA In Gastroenteritis Alone, Will Need To Co-Promote With Partner Or License Outright; Says Co. Has No Plans 'For any immediate or short-term financing from the financial markets'",2017-06-05 15:51:00-04:00,RDHL,negative
1071805.0,"UPDATE: RedHill Biopharma CEO Tells Benzinga Its BEKINDA In IBS-D Indication, If Successful, Will Have 'Significant Pricing Elasticity,' Notes IBS Treatments Are Expensive, Says 'Fully reimbursed, we can do very well in that market'",2017-06-05 15:51:00-04:00,RDHL,positive
1071806.0,"RedHill Biopharma Q1 EPS $(0.05) vs $(0.57) Est, No Sales",2017-05-03 06:21:00-04:00,RDHL,negative
1071807.0,RedHill Biopharma Reports Enrollment of Last Patient in BEKINDA Phase II Study for IBS-D,2017-04-24 07:12:00-04:00,RDHL,neutral
1071808.0,"RedHill Biopharma Offers Peer-Reviewed Publication of YELIVA Phase I Study Results: Confirmed Study Successfully Met Primary, Secondary Endpoints",2017-04-20 07:06:00-04:00,RDHL,positive
1071809.0,RedHill Biopharma Receives Notice of Allowance for 2 Additional U.S. Patents Covering BEKINDA,2017-04-18 08:04:00-04:00,RDHL,neutral
1071810.0,"IntelGenx, RedHill Biopharma Announce Marketing Approval of RIZAPORT for Migraines in Luxembourg",2017-04-13 06:03:00-04:00,RDHL,positive
1071811.0,RedHill Biopharma Reports Exclusive US License from Entera Health for EnteraGam,2017-04-05 07:05:00-04:00,RDHL,positive
1071812.0,18 Biggest Mid-Day Gainers For Tuesday,2017-04-04 12:38:00-04:00,RDHL,neutral
1071813.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-04-04 08:16:00-04:00,RDHL,neutral
1071814.0,RedHill Biopharma Gets Orphan Drug Designation for YELIVA,2017-04-04 06:07:00-04:00,RDHL,neutral
1071815.0,RedHill Biopharma Reports Initial Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn's Disease,2017-03-21 09:00:00-04:00,RDHL,neutral
1071816.0,"RedHill Biopharma Reports Q4 EPS $0.07 vs $0.05 in Same Qtr. Last Year, Sales $100K vs $3K YoY",2017-02-23 07:09:00-05:00,RDHL,neutral
1071817.0,RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis,2017-02-21 08:24:00-05:00,RDHL,neutral
1071818.0,UPDATE: RedHill Says Top-Line Results for BEKINDA Phase III Study Expected Q2'17,2017-02-13 08:06:00-05:00,RDHL,neutral
1071819.0,RedHill Reports Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis,2017-02-13 08:06:00-05:00,RDHL,neutral
1071820.0,20 Stocks Moving In Monday's Pre-Market Session,2017-01-23 08:19:00-05:00,RDHL,neutral
1071821.0,RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections,2017-01-11 08:11:00-05:00,RDHL,positive
1071822.0,RedHill Biopharma Reports First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection,2017-01-10 08:04:00-05:00,RDHL,positive
1071823.0,RedHill Biopharma to Present the 'Positive' Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium,2017-01-04 07:04:00-05:00,RDHL,neutral
1071824.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-01-03 08:11:00-05:00,RDHL,neutral
1071825.0,RedHill Biopharma Reports Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal,2017-01-03 07:03:00-05:00,RDHL,positive
1071826.0,Migdal Insurance & Financial Holdings Reports  4.76% Stake In RedHill Biopharma,2016-12-29 07:25:00-05:00,RDHL,neutral
1071827.0,15 Biggest Mid-Day Losers For Wednesday,2016-12-21 13:05:00-05:00,RDHL,negative
1071828.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-21 08:25:00-05:00,RDHL,neutral
1071829.0,RedHill Biopharma Announces Proposed Concurrent Public Offering and Registered Direct Offering,2016-12-20 16:03:00-05:00,RDHL,neutral
1071830.0,RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT,2016-12-14 08:05:00-05:00,RDHL,positive
1071831.0,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential of RHB-104 in Multiple Sclerosis,2016-12-12 08:05:00-05:00,RDHL,positive
1071832.0,Jefferies London Health Care Conference Continues Today,2016-11-17 10:14:00-05:00,RDHL,positive
1071833.0,RedHill Biopharma Reports Q3 EPS $0.07 vs. Est. $(0.58),2016-11-14 07:12:00-05:00,RDHL,neutral
1071834.0,RedHill Reports Positive FDA Type-B Meeting on RHB-105 for H. pylori Infection,2016-11-10 08:14:00-05:00,RDHL,positive
1071835.0,"RedHill Shares Up 3.5% This Morning; Co. Earlier Offered Update on Ongoing Phase III, II Studies with BEKINDA",2016-11-03 10:08:00-04:00,RDHL,positive
1071836.0,RedHill Biopharma Announces Withdrawal of Public Offering of its American Depositary Shares Due To Market Conditions,2016-11-02 09:21:00-04:00,RDHL,positive
1071837.0,18 Stocks Moving In Wednesday's Pre-Market Session,2016-11-02 08:43:00-04:00,RDHL,neutral
1071838.0,RedHill Biopharma Announces Allowance of a Patent in Japan Supporting RHB-104 for Multiple Sclerosis,2016-10-18 08:03:00-04:00,RDHL,positive
1071839.0,RedHill Biopharma Offers Update on RHB-104 Phase III Crohn's Disease Program,2016-10-06 07:02:00-04:00,RDHL,neutral
1071840.0,RedHill Biopharma Reports Initiation of Phase II Study with YELIVA in HC,2016-10-05 07:01:00-04:00,RDHL,neutral
1071841.0,RedHill Biopharma Reports Commercialization Term Sheet with IntelGenx for RIZAPORT,2016-09-21 08:02:00-04:00,RDHL,neutral
1071842.0,RedHill Biopharma Reports Phase Ib/II Study with YELIVA Initiated for Multiple Myeloma at a Leading U.S. Academic Medical Center,2016-09-08 08:01:00-04:00,RDHL,neutral
1071843.0,RedHill Recieves Notice of Intention to Grant A Patent For RHB-104 From the European Patent Office,2016-08-29 08:03:00-04:00,RDHL,positive
1071844.0,RedHill Biopharma Reports Q2 EPS $0.06 Does Not Compare to $(0.58) Estimate,2016-07-26 07:16:00-04:00,RDHL,neutral
1071845.0,RedHill BioPharma Reports Research Collab with NIH for Potential Ebola Treatment,2016-07-13 07:02:00-04:00,RDHL,neutral
1071846.0,"RedHill Biopharma, IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT for Migraines with Grupo JUSTE in Spain and Additional Potential Territories",2016-07-05 09:01:00-04:00,RDHL,positive
1071847.0,RedHill Biopharma Reports Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection,2016-06-22 08:01:00-04:00,RDHL,neutral
1071848.0,RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA in Advanced Solid Tumors,2016-06-21 09:25:00-04:00,RDHL,positive
1071849.0,"RedHill Reports Results of Phase 1 Study with YELIVA in Advanced Solid Tumors: Met Primary, Secondary Endpoints",2016-06-21 08:02:00-04:00,RDHL,positive
1071850.0,RedHill Biopharma Reports First Patients Dosed in Phase II Study with BEKINDA for IBS-D,2016-06-20 08:01:00-04:00,RDHL,neutral
1071851.0,RedHill Biopharma Reports National Cancer Institute Grant Supporting YELIVA Phase II Hepatocellular Carcinoma Study,2016-05-04 08:03:00-04:00,RDHL,neutral
1071852.0,RedHill Biopharma Reports Q1 EPS $0.04 vs. Est. $(0.51),2016-04-20 07:45:00-04:00,RDHL,neutral
1071853.0,"RedHill Biopharma Reports Results of FDA Meeting on RHB-105 Path to Approval, Planned Confirmation of Phase III Study for H. Pylori Infection",2016-04-18 08:08:00-04:00,RDHL,positive
1071854.0,RedHill Biopharma Starts Phase II Study of BEKINDA for Irritable Bowel Syndrome,2016-04-11 09:01:00-04:00,RDHL,negative
1071855.0,RedHill Biopharma Reports Interim Results from Phase IIa PoC Study Supporting Therapeutic Potential of RHB-104 in MS,2016-03-31 08:03:00-04:00,RDHL,positive
1071856.0,"RedHill Biopharma, IntelGenx Report RIZAPORT Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories",2016-03-29 07:03:00-04:00,RDHL,neutral
1071857.0,"RedHill Biopharma Clinical Study Report Confirms Positive Top-Line Results, Study Met Primary Endpoint eradication Levels Of 70% With High Statistical Significance",2016-03-08 08:03:00-05:00,RDHL,positive
1071858.0,"RedHill Biopharma Sees Phase 3 BEKINDA Study Expected 2nd Half 2016, To Initatie Confirmatory Phase 3 Study With RHB-105 Expected Q3 2015",2016-03-01 08:02:00-05:00,RDHL,neutral
1071859.0,RedHill Biopharma Reports Q4 Earnings $(6.56M) vs $(5.328M) in Same Qtr. Last Year,2016-02-25 08:18:00-05:00,RDHL,neutral
1071860.0,RedHill Biopharma Reports Notice of Allowance for US Patent Covering RIZAPORT for Migraines,2016-02-18 09:05:00-05:00,RDHL,neutral
1071861.0,RedHill Biopharma Announces Notice of Allowance for U.S. Patent Covering RIZAPORT for Migraines,2016-02-18 09:00:00-05:00,RDHL,neutral
1071862.0,"RedHill Biopharma Reports Successful PK Study with BEKINDA 12 mg, Submission of IBS-D Phase II Study Protocol",2016-02-11 09:01:00-05:00,RDHL,positive
1071863.0,RedHill Biopharam To Partner With Fraunhofer Institute for Oncology Drug RP101,2016-02-08 08:01:00-05:00,RDHL,neutral
1071864.0,Morning Market Gainers,2015-11-10 09:48:00-05:00,RDHL,neutral
1071865.0,RedHill Biopharma Reports Q3 EPS $(0.04) vs. Est. $(0.50),2015-11-09 07:19:00-05:00,RDHL,neutral
1071866.0,UPDATE: Redhill Phase I Study YELIVA Meets Primary & Secondary Endpoints,2015-10-26 08:05:00-04:00,RDHL,neutral
1071867.0,RedHill Biopharma Reports Positive Top-line Results from YELIVA Phase I Study in Advanced Solid Tumors,2015-10-26 08:05:00-04:00,RDHL,positive
1071868.0,RedHill Biopharma Gives Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D,2015-10-14 08:05:00-04:00,RDHL,neutral
1071869.0,5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm,2015-09-29 15:27:00-04:00,RDHL,neutral
1071870.0,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure,2015-09-10 09:05:00-04:00,RDHL,neutral
1071871.0,RedHill Biopharma Announces $2 Million National Cancer Institute Grant for YELIVA(TM) (ABC294640) Phase II Study for Multiple Myeloma,2015-09-09 08:05:00-04:00,RDHL,negative
1071872.0,RedHill Biopharma Announces Standard-of-Care Eradication Data From the RHB-105 Phase III Study Further Supporting the Study's Positive Results,2015-09-08 09:06:00-04:00,RDHL,positive
1071873.0,RedHill Biopharma Reports Peer-Reviewed Publication Showing Therapeutic Potential Of Yeliva In Prostate Cancer,2015-08-24 09:02:00-04:00,RDHL,negative
1071874.0,"Market Update: Google & Hertz Among Mid-Day Movers, Germany Votes In Favor Of Greece Bailout And More",2015-07-17 12:16:00-04:00,RDHL,positive
1071875.0,Morning Market Losers,2015-07-17 10:01:00-04:00,RDHL,negative
1071876.0,RedHill Biopharma Prices 2.462M ADS Offering @$16.25/ADS,2015-07-16 21:01:00-04:00,RDHL,neutral
1071877.0,US Stock Futures Edge Higher; Bank of America Earnings In Focus,2015-07-15 07:07:00-04:00,RDHL,neutral
1071878.0,RedHill Biopharma Extends Option Agreement for Phase II-Stage Pancreatic Cancer Drug RP101,2015-07-15 07:02:00-04:00,RDHL,negative
1071879.0,RedHill Biopharma Announces Offering of ADS,2015-07-14 16:15:00-04:00,RDHL,neutral
1071880.0,RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program,2015-07-01 07:01:00-04:00,RDHL,neutral
1071881.0,US Stock Futures Signal Lower Start On Wall Street,2015-06-29 07:28:00-04:00,RDHL,negative
1071882.0,RedHill Biopharma Initiates Phase I/II Study of ABC294640 for Refractory Lymphoma,2015-06-29 07:00:00-04:00,RDHL,neutral
1071883.0,"RedHill Bio Price Target Boosted To $32, Buy Reiterated",2015-06-17 09:00:00-04:00,RDHL,positive
1071884.0,US Stock Futures Decline Ahead Of Housing Starts Report,2015-06-16 07:22:00-04:00,RDHL,neutral
1071885.0,RedHill Biopharma Announces Acceptance of Phase III Trial Application in Europe with RHB-104 for Crohn's Disease,2015-06-16 07:02:00-04:00,RDHL,positive
1071886.0,Morning Market Gainers,2015-06-15 09:43:00-04:00,RDHL,neutral
1071887.0,RedHill Biopharma To Host Conference Call At 08:30 EDT Monday To Review Positive Phase III Top-Line Results With RHB-105 for H. Pylori Infection,2015-06-15 06:42:00-04:00,RDHL,positive
1071888.0,RedHill Biopharma Reports RHB-105 Phase 3 Study Meets Primary Endpoint,2015-06-15 06:06:00-04:00,RDHL,neutral
1071889.0,US Stock Futures Edge Lower Ahead Of Wholesale Inventories Data,2015-06-09 07:28:00-04:00,RDHL,negative
1071890.0,RedHill Biopharma Announces Completion of Patient Enrollment in the Phase IIa Study of RHB-104 for Multiple Sclerosis,2015-06-09 07:05:00-04:00,RDHL,neutral
1071891.0,RedHill Biopharama Announces Treatment of Last Patient With RHB-105 in Phase 3 Study,2015-06-08 07:01:00-04:00,RDHL,neutral
1071892.0,RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results,2015-06-03 07:02:00-04:00,RDHL,neutral
1071893.0,RedHill Biopharma Shares Move Higher; May be Attributed to Seeking Alpha Post,2015-05-05 10:33:00-04:00,RDHL,positive
1071894.0,RedHill Biopharma Completes Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection,2015-04-27 07:03:00-04:00,RDHL,neutral
1071895.0,RedHill Biopharma Receives Notice of Allowance for Additional US Patent for RHB-105 H. pylori Bacterial Infection Treatment,2015-04-16 07:05:00-04:00,RDHL,neutral
1071896.0,Benzinga's Top Initiations,2015-03-26 09:17:00-04:00,RDHL,positive
1071897.0,HC Wainwright Initiates Redhill Biopharma At Buy,2015-03-26 08:33:00-04:00,RDHL,neutral
1071898.0,"HC Wainwright Initiates Coverage on Redhill Biopharma at Buy, Announces $23.00 PT",2015-03-26 07:09:00-04:00,RDHL,neutral
1071899.0,Morning Market Losers,2015-02-10 10:00:00-05:00,RDHL,negative
1071900.0,"Morning-Market Movers Led By Aeropostale, Coca-Cola & Coupons.Com",2015-02-10 09:34:00-05:00,RDHL,neutral
1071901.0,Benzinga's Top #PreMarket Losers,2015-02-10 08:18:00-05:00,RDHL,negative
1071902.0,"Aeropostale, Idera Pharmaceuticals Lead Monday's After-Hours Movers",2015-02-09 18:07:00-05:00,RDHL,neutral
1071903.0,RedHill Biopharma Announces Proposed Public Offering of Its ADS Shares,2015-02-09 16:06:00-05:00,RDHL,positive
1071904.0,Roth Capital's 4 Reasons To Be Bullish On Titan Pharmaceuticals,2015-01-26 17:44:00-05:00,RDHL,neutral
1071905.0,"RedHill Biopharma Announces Business Outlook, Anticipated Key Milestones for 2015",2015-01-05 07:12:00-05:00,RDHL,neutral
1071906.0,Mid-Day Gainers From New Year's Eve 2014: NephroGenex And Other Biopharma Stocks,2014-12-31 12:42:00-05:00,RDHL,neutral
1071907.0,Morning Market Movers,2014-12-31 09:46:00-05:00,RDHL,neutral
1071908.0,Biotech Stocks Make Big Moves In Final Days Of 2014,2014-12-31 09:41:00-05:00,RDHL,neutral
1071909.0,RedHill Biopharma Acquires Technology from University of Minnesota,2014-12-18 06:07:00-05:00,RDHL,neutral
1071910.0,US Stock Futures Surge; Fed Decision In Focus,2014-12-17 07:18:00-05:00,RDHL,neutral
1071911.0,First Patients Enrolled in RedHill Biopharma Phase III Study of RHB-102 for Gastroenteritis and Gastritis,2014-12-17 06:10:00-05:00,RDHL,neutral
1071912.0,US Stock Futures Slip Ahead Of Wholesale Inventories Data,2014-12-09 07:12:00-05:00,RDHL,neutral
1071913.0,RedHill Biopharma Submits BEKINDA European Marketing Authorization Application for Oncology Support,2014-12-09 06:03:00-05:00,RDHL,positive
1071914.0,RedHill Biopharma To Sponsor And Exhibit Its Ongoing Phase III Crohn's Program At The Israeli IBD Society Meeting,2014-12-02 07:03:00-05:00,RDHL,neutral
1071915.0,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT For Migraines,2014-12-01 08:05:00-05:00,RDHL,positive
1071916.0,FDA Grants QIDP Fast-Track Designation to RedHill Biopharma's Phase III H. pylori Drug RHB-105,2014-11-10 07:32:00-05:00,RDHL,positive
1071917.0,RedHill Biopharma Initiates Phase III Study Of RHB-102 For Gastroenteritis,2014-09-03 07:03:00-04:00,RDHL,neutral
1071918.0,Morning Market Movers ,2014-07-17 09:45:00-04:00,RDHL,neutral
1071919.0,US Stock Futures Fall Ahead Of Home Sales Report,2014-06-30 07:20:00-04:00,RDHL,neutral
1071920.0,UPDATE: RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG ,2014-06-30 06:09:00-04:00,RDHL,neutral
1071921.0,RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON from WILEX AG,2014-06-30 06:06:00-04:00,RDHL,neutral
1071922.0,Events Scheduled for Week of Jun. 16th to Jun. 20th,2014-06-17 10:48:00-04:00,RDHL,neutral
1071923.0,"RedHill Biopharma Announces FDA Clearance for Phase III RHB-102, Expected to Start in Q3",2014-05-22 08:06:00-04:00,RDHL,neutral
1071924.0,RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study With RHB-103 to Support European Marketing Application Planned for Q3,2014-04-28 08:03:00-04:00,RDHL,positive
1071925.0,"RedHill Biopharma, IntelGenx Provide Update on FDA's Ongoing Review of NDA for RHB-103 Oral Migraine Film ",2014-04-24 08:06:00-04:00,RDHL,neutral
1071926.0,RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102,2014-04-07 08:04:00-04:00,RDHL,positive
1071927.0,RedHill Biopharma Pursuing New Indication for RHB-102,2014-03-07 07:07:00-05:00,RDHL,neutral
1071928.0,RedHill Biopharma Files $100M ADS Shelf Registration ,2014-01-23 13:32:00-05:00,RDHL,neutral
1071929.0,US Stock Futures Edge Higher; JPMorgan Earnings In Focus,2014-01-14 07:11:00-05:00,RDHL,neutral
1071930.0,RedHill Biopharma Announces $11.7M Private Placement Agreement,2014-01-14 06:02:00-05:00,RDHL,positive
1071931.0,RedHill Biopharma Announces $2.5M Private Placement from Broadfin Capital,2013-12-31 09:02:00-05:00,RDHL,neutral
1071932.0,US Stock Futures Edge Higher Ahead of Home Sales Report,2013-12-30 07:16:00-05:00,RDHL,neutral
1071933.0,RedHill Biopharma Announces $6M Private Placement From OrbiMed Israel Partners Limited Partnership ,2013-12-30 06:46:00-05:00,RDHL,negative
1071934.0,RedHill Biopharma Announces FDA Acceptance of IND Application for RHB-105 (H. pylori) Phase III Study - to Commence Shortly,2013-10-22 08:02:00-04:00,RDHL,positive
